



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

[Blood. 2009 Aug 27;114(9):1729-35. doi: 10.1182/blood-2009-04-205013.]

The definitive version is available at:

La versione definitiva è disponibile alla URL:

[<http://bloodjournal.hematologylibrary.org/content/114/9/1729.full.pdf+html>]

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Shaji Kumar, Sergio Giralto, Edward A. Stadtmauer, Jean L. Harousseau, Antonio Palumbo, William Bensinger, Raymond L. Comenzo, Suzanne Lentzsch, Nikhil Munshi, Ruben Niesvizky, Jesus San Miguel, Heinz Ludwig, Leif Bergsagel, Joan Blade, Sagar Lonial, Kenneth C. Anderson, Patrizia Tosi, Pieter Sonneveld, Orhan Sezer, David Vesole, Michele Cavo, Hermann Einsele, Paul G. Richardson, Brian G. M. Durie, S. Vincent Rajkumar on behalf of the International Myeloma Working Group (IMWG)

Abstract

The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure. Before the advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront setting, several reports have emerged raising concerns about their impact on the ability to collect stem cells. An expert panel of the International Myeloma Working Group (IMWG) was convened to examine the implications of these therapies on stem collection in patients with myeloma and to develop recommendations for addressing these issues. Here we summarize the currently available data and present our perspective on the problem and potential options to overcome this problem. Specifically, we recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization.

High-dose therapy and autologous stem cell transplantation for multiple myeloma

High-dose therapy and autologous stem cell transplantation (ASCT) remains an integral component of the myeloma treatment algorithm for patients considered eligible for the procedure. The majority of the randomized clinical trials have demonstrated a superior progression-free survival among patients undergoing ASCT compared with those treated with only conventional therapies and ASCT was associated with superior overall survival in 3 of those.¹⁻⁷ Subsequent randomized trials have further defined the role of ASCT by demonstrating equivalent overall survival for delayed transplantation compared with upfront ASCT, albeit with some compromise in the quality-of-life parameters.⁸ Introduction of novel agents such as thalidomide, lenalidomide, and bortezomib have resulted in a paradigm change in the therapy of myeloma.⁹⁻¹⁴ The high response rates with these agents, hitherto seen only in the context of high-dose therapy, have once again raised questions regarding the utility of ASCT in the setting of myeloma. Given the lack of long-term follow-up of patients treated with these new agents, the durability of these responses as well as their potential long-term adverse effects remain unknown and ASCT continues to be an important part of myeloma therapy.

Despite the increased use of the newer drugs for the initial treatment of myeloma, there is a continuous increase in the number of ASCTs reported to the Center for International Blood and Marrow Transplant Research (CIBMTR), highlighting their continued important role. Currently, the novel agents appear best

suited to be used as first-line therapy, enhancing the quality of responses prior to proceeding to ASCT and diminishing early mortality from the disease, or in selected patients as primary therapy, moving ASCT to a second-line position or as adjuncts to transplant conditioning regimens or as maintenance therapy in patients undergoing ASCT.^{15–23} Furthermore, in a randomized trial evaluating single versus double ASCT a survival advantage with tandem ASCT was demonstrated in an unplanned subset analysis for those patients not obtaining at least a very good partial response after the first ASCT. This observation has increased the number of ASCTs being performed for patients not achieving very good partial response after the first ASCT.²⁴ In addition, ASCT can also be used as part of second-line therapy after relapse, especially among patients who achieved a durable response after the first ASCT.^{6,23}

The traditional approach to patients with newly diagnosed myeloma, considered to be candidates for ASCT, has been to provide initial therapy with 4 to 6 cycles of a non-alkylator-containing regimen followed by collection of stem cells and high-dose therapy. The initial therapy for the disease allows time to obtain necessary insurance approvals as well as control disease-related symptoms, simultaneously controlling toxicity by limiting the number of cycles. In addition, adequate disease control provides an opportunity to reverse disease-related complications where feasible, and generally improve the functional status of the patient, allowing for a safer transplantation. Until the advent of the novel agents, the initial therapy regimens commonly used were vincristine, doxorubicin, and dexamethasone (VAD) or single-agent dexamethasone, both of which shared the advantage of having little impact stem cell mobilization and collection. Previous studies had shown that alkylating agents can potentially affect the stem cell pool and thus interfere with the ability to collect adequate numbers of stem cells.^{25–28}

The number of CD34⁺ cells collected for ASCT is dependent on a number of factors, most importantly the number of intended transplantations. The cell collection target usually depends on patient age, upfront versus delayed ASCT, patient preference, patient performance status, and presence of comorbidities, among others. Traditionally, the target for CD34 cell collection for a single ASCT has been 4 to 6 × 10⁶ CD34⁺/kg, with studies showing a deleterious impact on engraftment characteristics once the number falls below 2 × 10⁶ CD34⁺/kg.^{29,30} Use of more CD34 cells has not been consistently associated with any significant benefit in the parameters studied. Patient age is an important factor from several perspectives. Clearly there is decreasing use of stem cell transplantation (SCT) with increasing patient age, although selected patients with good performance status may undergo transplantation into their mid-70s. The target for stem cell collection is usually based on single transplantation in the United States, because Medicare reimburses only single SCT for myeloma. Finally, there is a clear impact of age on the ability to collect stem cells, with decreasing yield with advancing age.³¹ In the majority of patients undergoing an ASCT for myeloma, stem cells are collected from the peripheral blood following mobilization using growth factor administration with or without preceding chemotherapy. A minority of patients undergo ASCT with stem cells collected through a bone marrow harvest. Use of cyclophosphamide or other chemotherapy regimens for myelosuppression to achieve rebound CD34⁺ cell spillover into the blood with enhanced effects of myeloid growth factors during the recovery phase of peripheral blood counts allows for a more rapid stem cell collection and higher numbers of collected CD34⁺ cells compared with myeloid growth factor alone.^{32–35} Institutions differ in their standard approach for collecting stem cells, with pros and cons to either approach. Use of cyclophosphamide, although allowing better stem cell collection and less likelihood of a collection failure (less than the 2 × 10⁶ CD34⁺/kg), prolongs the collection process while awaiting count recovery and increases the risk of febrile neutropenia and other infectious complications.

One of the recent advances in the field of stem cell mobilization strategies has been the introduction of AMD3100 (plerixafor), a receptor chemokine receptor 4 (CXCR4) inhibitor. Previous studies have

highlighted the role of CXCR4 in the stem cell mobilization induced by granulocyte colony-stimulating factor (G-CSF) and cyclophosphamide. Lévesque et al showed that mobilization of stem cells by G-CSF coincides in vivo with the cleavage of the N-terminus of the chemokine receptor CXCR4 on the stem cells in the BM, leading to loss of chemotaxis in response to the CXCR4 ligand, the chemokine stromal cell–derived factor-1 (SDF-1/CXCL12).³⁶ In addition, accumulation of serine proteases led to cleavage and inactivation of SDF-1. Originally developed as an anti-HIV drug, the ability of this drug to enhance peripheral mobilization of CD34⁺ cells was subsequently recognized. AMD3100, a reversible inhibitor of the binding of stromal cell–derived factor-1α (SDF-1α, also known as CXCL12) to its cognate CXCR4, has been shown to increase the number of circulating CD34⁺ cells in healthy volunteers when administered alone or with G-CSF prior to treatment.^{37–39} Stem cells express CXCR4 and are known to migrate to the bone marrow through a chemoattractant effect of SDF-1α that is produced locally by bone marrow stromal cells. Once in the marrow, it is also believed that stem cell CXCR4 can act to help “anchor” these cells to stromal cell surface SDF-1α. AMD3100-induced leukocytosis and elevations in circulating hematopoietic progenitor cell levels are thought to result from a disruption of the CXCR4/CXCL12 interaction and cell adhesion effects, resulting in the appearance of both mature and pluripotent cells in the systemic circulation. AMD3100 has been shown to exert an additive effect on the number of circulating hematopoietic stem and progenitor cells when administered with G-CSF. AMD3100-3102 was a multicenter randomized, double-blind, placebo-controlled comparative trial designed to examine the ability of 240 µg/kg AMD3100 plus G-CSF versus placebo plus G-CSF to mobilize CD34⁺ stem cells in patients with multiple myeloma (MM), who had not previously failed stem cell collections and had not received previous stem cell transplant. The primary end point, the percentage of patients who achieved 6×10^6 or more CD34⁺ cells/kg in 2 or fewer apheresis days, was met in 106 (72%) of 128 patients in the AMD plus G-CSF group and 53 (34%) of 154 patients in the placebo plus G-CSF group, ($P < .001$). Fifty-four percent of study patients reached target after 1 day of apheresis in the AMD + G-CSF group compared with 17.3% in the placebo plus G-CSF group. After 4 days of apheresis, these numbers were 86.8% and 56%, respectively.⁴⁰

Thalidomide-, lenalidomide-, or bortezomib-based regimens as initial therapy for multiple myeloma

Introduction of thalidomide represented the first major therapeutic advance in myeloma in several decades. After the initial trials in relapsed myeloma, several randomized phase 3 trials of thalidomide and dexamethasone in patients with previously untreated myeloma were performed.^{15,18,41,42} Thalidomide combinations were associated with superior response rates and improved response duration with no definite impact on the overall survival compared with dexamethasone alone or VAD. This was followed by introduction of the thalidomide analog, lenalidomide, that in phase 2 trials resulted in very high response rates as well as deeper responses than were seen with previous approaches.^{11,43} Subsequent phase 3 trials of lenalidomide and dexamethasone demonstrated its superiority compared with dexamethasone alone as well as its ability to spare high doses of steroids and simultaneously improve survival.^{12,19} More recent clinical trials have examined the efficacy and tolerability of lenalidomide combined with cyclophosphamide (CTX), bortezomib, and clarithromycin, as well as other combinations.^{44–46} Another major advance in the field had been the introduction of the proteasome inhibitor bortezomib, which along with dexamethasone or in combination with conventional chemotherapy agents is increasingly being used in the setting of newly diagnosed disease with high efficacy. Phase 3 trials of bortezomib in combination with dexamethasone with or without doxorubicin has shown excellent tolerability and improved response rates and progression-free survival compared with traditional VAD in the setting of initial therapy prior to SCT.^{17,20,47} Both lenalidomide and bortezomib have been combined with cyclophosphamide in the setting of transplantation-eligible

patients in phase 2 studies with excellent response rates.^{48,49} Recently reported phase 2 trials have examined the efficacy of combining bortezomib with lenalidomide or thalidomide with or without cyclophosphamide in the setting of newly diagnosed MM.⁵⁰⁻⁵³ These combinations have led to very high complete and very good partial response rates and will undoubtedly become integral components of the initial treatment choices in the future. This in turn has led to renewed interest in the potential impact of initial therapy on the ability to collect adequate numbers of stem cells for one or more transplantations.

Impact of thalidomide, lenalidomide, and bortezomib on peripheral blood stem cell collection

A large volume of data, albeit limited to single institution reports and less detailed data from phase 3 trials, has appeared in the past few years evaluating the effect of these new drugs on the stem cell collection process (Table 1). Although there are contradictory data on the impact of thalidomide on stem cell mobilization and collection, the effect if any appears to be relatively small with limited impact on the ability to proceed with SCT.^{15,18,33,54} In addition, there is no evidence to suggest that initial therapy with thalidomide-containing regimens prior to stem cell collection adversely impacts the engraftment potential of the collected stem cells.

Table 1

Table 1. Studies of novel agents with data available for success of stem cell collection

Reference	Treatment regimen	No.	Clinical trial	Mobilization regimen	CD34 yield, × 10 ⁶ /kg	P	Days of leukapheresis	Failed collection % (definition)
Brotkreutz et al ⁴⁴	TAD	93	Phase 3 (GMMG-HD3)	CAD	9.8 (2-33.6)	.02	1 (1-6)	4 (< 2.5 × 10 ⁶ /kg)
	VAD	105			10.9 (3-36)		1 (1-7)	7
Brotkreutz et al ⁴⁴	TAD	100	Phase 3 (HOVON-50)	CAD	7.4 (2-33)	.009	1 (1-4)	3 (< 2.5 × 10 ⁶ /kg)
	VAD	100			9.4 (0-48.7)		1 (1-4)	5
Rajkumar et al ⁵²	TD	99	Phase 3 (E1A00)	Various	NA	NA	NA	10 (NA)
	D	100			NA		NA	10
Cavo et al ¹⁸	TD	100	Matched pair analysis	CTX + G-CSF	7.85	.4	2	17 (< 4 × 10 ⁶ /kg)
	VAD	100			10.5		2	12
Kumar et al ³³	Dax	78	Retrospective	G-CSF	9.6 (1-18)	< .01	3 (1-10)	1 (< 2.5 × 10 ⁶ /kg)
	VAD	22			9.8 (2.1-16.2)		4 (2-10)	1
	TD	99			10.0 (3.5-30.1)		4 (1-10)	0
	LD	43			7.9 (0-15.6)		5 (1-12)	3
Mazumder et al ⁴⁴	LD	28	Retrospective	G-CSF	5.4 (0-17.5)	NA	NA	43 (< 2 × 10 ⁶ /kg)
Parpali et al ⁴⁴	Other	41	Retrospective	G-CSF	7.4	.003		7.3 (< 2 × 10 ⁶ /kg)
	LD	20			5.1			45
Rajkumar et al ⁵² †	Ld	223	Phase 3 (E4A03)	Various	NA	NA		3 (NA)
	Ld	220			NA			3 (NA)
Kumar et al ⁴⁷	LD/Ld	92	Retrospective	G-CSF	7.9 (0-16)	NA		11 (< 2.5 × 10 ⁶ /kg)
		11		CTX + G-CSF	8.6 (0-21)			
Mark et al ⁴²	BFD	9	Retrospective	G-CSF	3.1 (0.2-8.6)	< .01		3 (< 4 × 10 ⁶ /kg)
		19		CTX + G-CSF	14.2 (4.9-236)			0
Cook et al ⁴⁸	LD	21	Retrospective	CTX + G-CSF	6.3 (2.4-19.7)		3 (1-8)	9 (< 2.5 × 10 ⁶ /kg)
		137		(4 with G-CSF ± AMD9100)	7.3 (2.4-72.5)		2 (1-11)	1.5
Popat et al ⁴⁰	LD	64	Retrospective	G-CSF	NA			25 (< 2 × 10 ⁶ /kg in 4 days)
	Other	238						4
Jagannath et al ²¹	BD	8			13-20 (7.2-16.1)		2 (2-3)	0
Harousseau et al ¹⁷	BD	240	Phase 3 (IFM 2005-01)	G-CSF	6.8		2.0 (mean)	4 (< 2 × 10 ⁶ /kg)
	VAD	242			8.4		1.6 (mean)	2
Sonnwald et al ⁵⁰	BAD	150	HOVON-65	CTX + G-CSF	10.48 (4-37)		1 (1-5)	
	VAD	150			9.26 (4.1-37.6)		1 (1-4)	
Richardson et al ⁵¹	VRD	23	Phase 2	G-CSF	6.2			8.7

TAD indicates thalidomide, doxorubicin, and dexamethasone; VAD, vincristine, doxorubicin, and dexamethasone; CAD, cyclophosphamide 1 g/m² per day, iv, on day 1; doxorubicin 15 mg/m² per day, iv, on days 1 to 4; dexamethasone 40 mg orally, days 1-4, and granulocyte colony-stimulating factor (G-CSF); NA, not available; TD, thalidomide, dexamethasone; CTX, cyclophosphamide; LD, lenalidomide, dexamethasone; Ld, lenalidomide and weekly dexamethasone; and BD, bortezomib and dexamethasone.

*Information on whether a stem cell harvest was attempted was available only for 79% of patients, among whom 37% attempted stem cell harvest. Collection details were not available.

†Details of stem cell collection regarding cell counts and definition of failure were not available and are likely to represent a mix of practices given the multicenter nature of trial.

Studies of novel agents with data available for success of stem cell collection

In contrast to thalidomide, one of the common adverse effects of lenalidomide has been hematologic toxicity, especially myelosuppression. This finding raised concern that use of lenalidomide could adversely affect the ability to mobilize and collect adequate numbers of CD34⁺ cells for ASCT. In 2 large studies from Mayo Clinic and M. D. Anderson, the most significant factor influencing the ability to collect adequate numbers of stem cells appeared to be initial therapy with lenalidomide (Table 1).^{33,60} In addition to lenalidomide therapy, other important factors impacting the stem cell collection appeared to be the patient age and the duration of lenalidomide therapy.^{33,60} The failure rate of mobilization following lenalidomide therapy has varied significantly between the different studies, likely a reflection of the lenalidomide treatment duration, age of the patient population undergoing stem cell collection, mobilization regimens, and collection targets used. However, data so far do not indicate any impact on the quality of stem cells collected, as reflected in the engraftment kinetics as well as success.^{12,55,56}

The effect of bortezomib on the ability to collect stem cells has also been examined in the context of phase 2 and 3 trials examining the combinations (Table 1).^{17,21,49,61} Although no definite impact of initial therapy on stem cell harvest was demonstrated in the smaller phase 2 studies of bortezomib and dexamethasone,²¹ in the IFM 2005/01 trial comparing bortezomib/dexamethasone to VAD there was a trend toward lower CD34 numbers among those receiving bortezomib.¹⁷ In contrast, in the HOVON-65/GMMG-HD4 randomized phase 3 trial comparing bortezomib, adriamycin, dexamethasone (PAD) versus VAD as induction treatment, no impact of the regimen was seen on the ability to collect stem cells.⁶² No significant impact of initial therapy has been seen in other trials that have combined the novel agents, bortezomib in combination with either lenalidomide or thalidomide.^{51,63} Addition of alkylating agents to the initial therapy, especially in combination, may increase the risk of collection failures, but no comparative data are available.^{48,49} In a phase 2 study looking at the combination of lenalidomide with cytoxan and dexamethasone for newly diagnosed myeloma, we observed 8 of 30 failures at mobilization.⁴⁸ In contrast, in a phase 2 study of cytoxan, bortezomib, and dexamethasone by Reeder et al, all patients who attempted stem cell collection were able to get enough cells for at least one transplantation.⁴⁹

Although there has been a wide spectrum of reported data on the initial therapy with a novel agent and the ability to collect stem cells, some common themes have emerged. In the 2 larger experiences published to date of lenalidomide therapy prior to harvest, the number of cycles of therapy appears to be important.^{33,60} Although none of the patients with fewer than 6 cycles of lenalidomide failed to collect stem cells in the Mayo Clinic series, more than 3 cycles of lenalidomide were associated with a higher risk in the M. D. Anderson series. However the smaller studies have not demonstrated such a relationship, and in the absence of detailed data from the larger prospective studies, it would be reasonable to assume that longer duration of therapy will increase the risk of failure. Another common finding has been the age of the patients, with more than one study demonstrating increased likelihood of failure in the older patients.^{33,60} In these 2 studies, no relationship was noted between the time off lenalidomide prior to stem cell harvest. Another important finding across the studies has been the low incidence of collection failure among patients mobilized with chemotherapy, typically cyclophosphamide, and G-CSF.^{58,59} Among 28 treatment-naïve patients treated with the combination of clarithromycin, lenalidomide, and dexamethasone (BIRD) reported by Mark et al, sufficient stem cells for 2 autologous stem cell transplantations were collected from all patients mobilized with CTX plus G-CSF, versus 33% mobilized with G-CSF alone, demonstrating that this approach can potentially overcome the impairment in stem cell mobilization associated with lenalidomide.⁵⁸ For patients failing initial attempts at stem cell mobilization with G-CSF alone, chemotherapy + G-CSF approach appears to have a reasonable efficacy. Five of 7 patients failing G-CSF alone were successfully mobilized with CTX + G-CSF in one study⁵⁷ and 18 of 21 patients were remobilized successfully with a chemotherapy + G-CSF approach in another study.⁶⁰ Mazumder et al also reported 3

patients who failed to collect successfully despite undergoing mobilization with the CXCR4 inhibitor plerixafor, but were subsequently collected using a combination of cyclophosphamide and G-CSF.⁵⁵

Potential mechanisms of the impact of lenalidomide treatment on stem cell collection

The exact mechanism why lenalidomide inhibits stem cell mobilization is not clear. Koh et al investigated the effects of lenalidomide, pomalidomide (CC4047) (IMiDs), and thalidomide on CD34⁺ hematopoietic progenitors. They showed in human colony formation assays and long-term culture-initiating cell tests that IMiDs and thalidomide are not toxic to hematopoietic stem cells and do not inhibit self-renewal capacity of stem cells.⁶⁴ This makes it less likely that a direct toxic effect of lenalidomide on hematopoietic progenitors explains the limitation in stem cell collection. The group further showed that IMiDs promote myelopoiesis with a concomitant maturation stop of neutrophil granulocytes by down-regulation of critical transcription factors such as PU.1. This leads to an accumulation of immature granulocytes within the bone marrow compartment and neutropenia in the peripheral blood.⁶⁵ Interestingly, the group also observed that the G-CSF secretion is highly up-regulated in cultures of hematopoietic progenitors treated with IMiDs (day 3 of treatment: control 140 pg/mL, lenalidomide 800 pg/mL, CC4047 1500 pg/mL)⁶⁴ (S.L., written communication, September 2008). The biologic reason for the strong up-regulation of G-CSF is unknown. It is likely that self-regulatory mechanisms up-regulate G-CSF to overcome the maturation stop of granulocytes. Higher levels of G-CSF might lead to a tachyphylactic response, resulting in resistance to G-CSF mobilization. These findings are also supported by our observation that all other “non-G-CSF-based” mobilization approaches such as CTX and AMD3100 are successful in mobilizing a sufficient CD34⁺ cell number.

Suggested approach to stem cell collection in patients undergoing initial therapy with novel agents

In June 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell collection for autologous transplantation in patients receiving therapy with lenalidomide. The following statements reflect the considerations of the panel and the consensus recommendations formulated by the panel. The recommendations take into account the existing data suggesting compromised collection with the newer agents in some of the patients as well as the data, although limited, examining alternate approaches to stem cell mobilization. These recommendations will be revised when additional data become available, enabling us to make more specific recommendations.

First attempt: Given the potential for the novel agents to impact the ability of the stem cell collection, we recommend early stem cell mobilization when SCT is being contemplated immediately or later in the course of disease. Such an approach, after 3 to 4 cycles of initial therapy, is quite feasible given the rapid response seen with the new combinations. However, there exists considerable confusion at this point in terms of the mechanisms mediating the decreased collection as well as the best approaches to prevent this problem, and every effort should be made to enroll these patients in clinical trials evaluating these questions.

Among patients undergoing initial therapy with thalidomide or bortezomib in combination with dexamethasone or among those treated with lenalidomide and dexamethasone who have received fewer than 4 cycles of therapy and are younger than 65 years, G-CSF alone is considered adequate for the initial attempt at mobilizing stem cells, although many centers will continue to use cyclophosphamide and G-CSF as their standard protocol. Among those who have received more than 4 cycles of lenalidomide therapy,

one should consider the initial use of cyclophosphamide and G-CSF for mobilization. This suggestion is based on the findings of increased failure risk in this population as well as the reduced risk of failure associated with the use of cyclophosphamide and G-CSF. Although the use of cyclophosphamide in all patients is likely to decrease the risk of failure at first attempt, the recommendation to use G-CSF alone in the former group is driven by the low risk of failure in that group, the increased risks and delay associated with use of cyclophosphamide, and finally the ability to successfully collect with cyclophosphamide and G-CSF in the few patients who fail the initial attempt with G-CSF alone. In patients older than 65 years old, we recommend consideration of reduced-dose cyclophosphamide with G-CSF or G-CSF alone with addition of AMD-3100 before the second leukapheresis if the first leukapheresis results in less than 2 million CD34⁺ cells/kg. In patients receiving other myelosuppressive drugs in combination with lenalidomide, cyclophosphamide and G-CSF should be considered for the initial attempt as the rate of failure increases in these situations. There are no data supporting additional time off therapy prior to mobilization enhancing the likelihood of a successful mobilization. We do not recommend a minimum period that patients have to be off lenalidomide prior to starting G-CSF for mobilization.

Failed stem cell collection

Among patients receiving initial therapy with lenalidomide-containing regimens failing to collect with G-CSF alone, there are 3 options for the subsequent attempt. The majority of the patients can be collected with cyclophosphamide priming and G-CSF. These patients will be candidates for use of AMD3100, which in combination with G-CSF has been very successful in mobilizing stem cells. Another approach includes the use of a combination of G-CSF and granulocyte-macrophage colony-stimulating factor (10 µg/kg per day subcutaneously for 2 days, followed by G-CSF 16 µg/kg per day subcutaneously until stem cell collection is complete).

Upfront use of plerixafor (AMD3100) in lenalidomide-treated patients

The panel discussed the question of routine use of plerixafor for mobilization in this patient group. It was felt that at this time, without a detailed cost benefit analysis, such a recommendation cannot be made and additional clinical trials specifically addressing its use in these patients will allow us to answer this question. Prospective trials should be conducted to study the use of plerixafor in patients failing to reach certain thresholds for peripheral blood CD34 counts.

References

1. Attal M, Harousseau JL, Stoppa AM, et al . *A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.*
2. Barlogie B, Kyle RA, Anderson KC, et al . *Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929-936.*
3. Bladé J, Rosinol L, Sureda A, et al . *High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106:3755-3759.*

4. Child JA, Morgan GJ, Davies FE, et al . *High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.*
5. Femand JP, Katsahian S, Divine M, et al . *High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227-9233.*
6. Femand JP, Ravaud P, Chevret S, et al . *High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-3136.*
7. Palumbo A, Bringhen S, Petrucci MT, et al . *Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052-3057.*
8. Femand JP, Ravaud P, Chevret S, et al . *Early versus late high dose therapy (HDT) and autologous peripheral blood stem cell transplantation in multiple myeloma (MM): results of a prospective randomized trial [abstract]. Blood 1996;88 suppl 1:685a.*
9. Rajkumar SV, Blood E, Vesole DH, Fonseca R, Greipp PR . *Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436.*
10. Rajkumar SV, Hayman S, Gertz MA, et al . *Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-4323.*
11. Rajkumar SV, Hayman SR, Lacy MQ, et al . *Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-4053.*
12. Rajkumar SV, Jacobus S, Callander N, et al . *Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. J Clin Oncol 2007;25(18S):LBA8025. (ASCo Annual Meeting Abstracts).*
13. Richardson P, Chanan-Khan A, Schlossman R, et al . *A multicenter phase II trial of bortezomib in patients with previously untreated multiple myeloma: efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy [abstract]. Blood 2005;106:2548. (ASH Annual Meeting Abstracts).*
14. Richardson P, Jagannath S, Raje N, et al . *Lenalidomide, Bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase 1/2 study [abstract]. Blood 2007;110:187. (ASH Annual Meeting Abstracts).*
15. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR . *Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436.*

16. Rajkumar SV, Jacobus S, Callander N, et al . *Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome with primary therapy and with stem cell transplantation [abstract]. J Clin Oncol 2008;26:8504. (Meeting Abstracts).*
17. Harousseau JL, Mathiot C, Attal M, et al . *Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J Clin Oncol 2008;26:8505. (Meeting Abstracts).*
18. Cavo M, Zamagni E, Tosi P, et al . *Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-39.*
19. Zonder JA, Crowley J, Hussein MA, et al . *Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232 [abstract]. Blood 2007;110:77. (ASH Annual Meeting Abstracts).*
20. Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al . *First analysis of HOVON-65/GMMG-HD4 randomized phase iii trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood 2008;112:653. (ASH Annual Meeting Abstracts).*
21. Jagannath S, Durie BG, Wolf J, et al . *Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-783.*
22. Attal M, Harousseau JL, Leyvraz S, et al . *Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289-3294.*
23. Abdelkefi A, Ladeb S, Torjman L, et al . *Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008;111:1805-1810.*
24. Attal M, Harousseau JL, Facon T, et al . *Single versus double autologous stem-cell transplantation for multiple myeloma [see comment]. N Engl J Med 2003;349:2495-2502.*
25. Knudsen LM, Rasmussen T, Jensen L, Johnsen HE . *Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment. Med Oncol 1999;16:245-254.*
26. de la Rubia J, Blade J, Lahuerta JJ, et al . *Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma: results of the Spanish Myeloma Group (GEM) Study. Haematologica 2006;91:621-627.*

27. Boccadoro M, Palumbo A, Bringhen S, et al . *Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica* 2002;87:846-850.
28. Jansen J, Thompson J, Dugan M, et al . *Impaired PBPC collection in patients with myeloma after high-dose melphalan. Cytotherapy* 2004;6:498-504.
29. Bensinger W, Appelbaum F, Rowley S, et al . *Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol* 1995;13:2547-2555.
30. Desikan KR, Tricot G, Munshi NC, et al . *Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol* 2001;112:242-247.
31. Morris CL, Siegel E, Barlogie B, et al . *Mobilization of CD34+ cells in elderly patients (>= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol* 2003;120:413-423.
32. Iegre A, Tomas JF, Martinez-Chamorro C, et al . *Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant* 1997;20:211-217.
33. Kumar S, Dispenzieri A, Lacy MQ, et al . *Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia* 2007;21:2035-2042.
34. Arora M, Burns LJ, Barker JN, et al . *Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant* 2004;10:395-404.
35. Hiwase DK, Bollard G, Hiwase S, Bailey M, Muirhead J, Schwarzer AP. *Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy* 2007;9:539-547.
36. Lévesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ . *Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by G-CSF or cyclophosphamide. J Clin Invest* 2003;111:187-196.
37. Donzella GA, Schols D, Lin SW, et al . *AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med* 1998;4:72-77.
38. Liles WC, Broxmeyer HE, Rodger E, et al . *Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood* 2003;102:2728-2730.
39. Devine SM, Flomenberg N, Vesole DH, et al . *Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol* 2004;22:1095-1102.

40. DiPersio J, Stadtmauer EA, Nademanee AP, et al . *A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [abstract]. Blood 2007;110:445. (ASH Annual Meeting Abstracts).*
41. Rajkumar SV, Rosinol L, Hussein M, et al . *Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171-2177.*
42. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al . *Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008;93:124-127.*
43. Lacy M, Gertz M, Dispenzieri A, et al . *Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179-1184.*
44. Kumar S, Hayman SR, Buadi FK, et al . *Phase II trial of lenalidomide, cyclophosphamide, and dexamethasone (CRd) for newly diagnosed myeloma. [abstract]. Blood 2007;110:190. (ASH Annual Meeting Abstracts).*
45. Richardson PG, Lonial S, Jakubowiak A, et al . *Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): a phase I/II study [abstract]. J Clin Oncol 2008;26:8520. (Meeting Abstracts).*
46. Niesvizky R, Jayabalan DS, Christos PJ, et al . *BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111:1101-1109.*
47. Rosiñol L, Oriol A, Mateos MV, et al . *Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007;25:4452-4458.*
48. Kumar S, Hayman S, Buadi F, et al . *Phase II trial of lenalidomide (RevlimidTM) with cyclophosphamide and dexamethasone (RCd) for newly diagnosed myeloma [abstract]. Blood 2008;112:91. (ASH Annual Meeting Abstracts).*
49. Reeder CB, Reece DE, Kukreti V, et al . *Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009;23:1337-1341.*
50. Kumar S, Flinn IW, Noga SJ, et al . *Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: initial results from the phase I/II multi-center EVOLUTION Study [abstract]. Blood 2008;112:93. (ASH Annual Meeting Abstracts).*

51. Richardson P, Lonial S, Jakubowiak A, et al . *Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase i/ii study [abstract]. Blood 2008;112:92. (ASH Annual Meeting Abstracts).*
52. Cavo M, Tacchetti P, Patriarca F, et al . *Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood 2008;112:158. (ASH Annual Meeting Abstracts).*
53. Rosinol L, Cibeira MT, Martinez J, et al . *Thalidomide/dexamethasone (TD) vs. bortezomib (Velcade(R))/thalidomide/dexamethasone (VTD) vs. VBMCP/VBAD/Velcade(R) as induction regimens prior autologous stem cell transplantation (ASCT) in younger patients with multiple myeloma (MM): first results of a prospective phase III PETHEMA/Gem Trial [abstract]. Blood 2008;112:654. (ASH Annual Meeting Abstracts).*
54. Breitzkreutz I, Lokhorst HM, Raab MS, et al . *Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007;21:1294-1299.*
55. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S . *Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008;22:1280-1281. author reply: 1281–1282.*
56. Paripati H, Stewart AK, Cabou S, et al . *Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008;22:1282-1284.*
57. Kumar S, Lacy M, Dispenzieri A, et al . *Stem cell mobilization following initial therapy with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma [abstract]. Blood 2008;112:3467. (ASH Annual Meeting Abstracts).*
58. Mark T, Stern J, Furst JR, et al . *Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008;14:795-798.*
59. Cook RJ, Vogl D, Mangan PA, et al . *Lenalidomide and stem cell collection in patients with multiple myeloma [abstract]. J Clin Oncol 2008;26:8547. (Meeting Abstracts).*
60. Popat U, Saliba R, Thandi R, et al . *Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009;15:718-723.*
61. Jagannath S, Durie BG, Wolf J, et al . *Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-783.*
62. Goldschmidt H, Lokhorst HM, Bertsch U, et al . *Successful harvesting of peripheral hematopoietic stem cells after induction treatment with bortezomib, adriamycin, dexamethasone (PAD) in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood 2008;112:3470. (ASH Annual Meeting Abstracts).*

63. Bensinger W, Jagannath S, Vescio R, et al. *A phase II study of bortezomib (Velcade (R)), cyclophosphamide (cytoxan(R)), thalidomide (thalamid(R)) and dexamethasone as first-line therapy for multiple myeloma [abstract]. Blood 2008;112:94. (ASH Annual Meeting Abstracts).*
64. Koh KR, Janz M, Mapara MY, et al. *Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 2005;105:3833-3840.*
65. Anderson G, Gries M, Kurihara N, et al. *Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006;107:3098-3105.*